In trials evaluating pembrolizumab and anti–CTLA-4 antibody in advanced HCC, 9 and 19% of patients exhibited an increase in ALT of any grade, while 4 and 9% an increase of grade ≥3, respectively (Duffy et al., 2017; Zhu et al., 2018). This evidence concerns the gene GPT and hepatocellular carcinoma.